Patient-reported outcomes from two global multicenter clinical trials of children and adults with tropomyosin receptor kinase (TRK) fusion cancer receiving larotrectinib. Kummar, S., Mascarenhas, L., Geoerger, B., Turpin, B., Cox, M., Yu, S., Nanda, S., Hiemeyer, F., Keating, K. N., Chirila, C., Gnanasakthy, A., Davenport, E., Hong, D. S., Drilon, A. E. AMER SOC CLINICAL ONCOLOGY. 2019

View details for DOI 10.1200/JCO.2019.37.15_suppl.6602

View details for Web of Science ID 000487345806156